Shares of Pozen Inc. jumped 14.6 percent Tuesday on news that U.S. commercialization of Vimovo, its approved gastric-friendly nonsteroidal inflammatory drug, would be transferring to specialty pharma Horizon Pharma USA Inc., a company that has shown early success in marketing its own similar combo product, Duexis.